Clorox Says No To Icahn's $10.2B Buyout Bid

citizen |

Analysts were uncertain a competitor would want to acquire Clorox, which does most of its business in the mature U.S. markets and is not a big player in faster-growing overseas markets. Photo Vox Efx
Analysts were uncertain a competitor would want to acquire Clorox, which does most of its business in the mature U.S. markets and is not a big player in faster-growing overseas markets. Photo Vox Efx

NEW YORK (AP) - Clorox Co. is turning down billionaire investor Carl Icahn's offer to buy the company, saying the price of $76.50 per share is too low.

The Oakland, Calif., company is also adopting a poison pill shareholder rights measure to ward off the bid from Icahn, who is the largest shareholder in Clorox. The company says it is committed to its current strategy, saying its own plans are the best way to create value for its shareholders.

Recently, Icahn Enterprises LP offered to buy Clorox for $10.2 billion in cash. Rather than urge the company to take the unsolicited offer, Icahn said Clorox should shop itself to competitors, saying it could get a better offer from companies like Procter & Gamble, Colgate-Palmolive Co., or Kimberly-Clark Corp.

Associated Press text, photo and/or graphic material shall not be published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. Neither these AP Materials nor any portion thereof may be stored in a computer except for personal and non-commercial use. The AP will not be held liable for any delays, inaccuracies, errors or omissions therefrom or in the transmission or delivery of all or any part thereof or for any damages arising from any of the foregoing.

Latest Stories

Latest Podcast

Learning To Live Life Correctly By Knowing Your Blood Type